Specific overexpression of tumour necrosis factor-α-induced protein (TNFAIP)9 in CD14+CD16- monocytes in patients with rheumatoid arthritis: Comparative analysis with TNFAIP3

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 458-466

  Takai, C ^a,b   Matsumoto, I ^a   Inoue, A ^a   Umeda, N ^a   Tanaka, Y ^a   Kurashima, Y ^a   Wada, Y ^b   Narita, I ^b   Sumida, T ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Monocytes; Pathogenesis; Rheumatoid arthritis; TNF induced proteins; TNFAIP9

Indexed keywords

ABATACEPT; CD14 ANTIGEN; CD16 ANTIGEN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 9; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; DNA BINDING PROTEIN; FC RECEPTOR; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; OXIDOREDUCTASE; SIGNAL PEPTIDE; STEAP4 PROTEIN, HUMAN; TNFAIP3 PROTEIN, HUMAN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL THERAPY; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CELL POPULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD14; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; NUCLEAR PROTEINS; OXIDOREDUCTASES; RECEPTORS, IGG; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929327127     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12606     Document Type: Article

References (33)

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
2. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214:149-60.
3. Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 2013; 4:653-66.
4. Inoue A, Matsumoto I, Tanaka Y et al. Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R118.
5. Inoue A, Matsumoto I, Tanaka Y et al. Murine tumor necrosis factor α-induced adipose-related protein (tumor necrosis factor α-induced protein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF-κB, STAT-3 signaling, and dysregulated apoptosis of macrophages. Arthritis Rheum 2012; 64:3877-85.
6. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-κB signaling. Cell Res 2011; 21:22-39.
7. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 2000; 29:2350-4.
8. Matmati M, Jacques P, Maelfait J et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011; 14:908-12.
9. Matsumoto I, Inoue A, Takai C et al. Regulatory roles of tumor necrosis factor alpha-induced proteins (TNFAIPs) 3 and 9 in arthritis. Clin Immunol 2014; 153:73-8.
10. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against rheumatism criteria. Arthritis Rheum 1996; 39:34-40.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
12. Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995; 15:1699-706.
13. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-80.
14. Zawada AM, Rogacev KS, Rotter B et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118:e50-61.
15. Tanaka Y, Matsumoto I, Iwanami K et al. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012; 30:99-102.
16. Tanaka Y, Matsumoto I, Iwanami K et al. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis. Mod Rheumatol 2012; 22:128-36.
17. Noh R, Park SG, Ju JH et al. Comparative proteomic analyses of synovial fluids and serums from rheumatoid arthritis patients. J Microbiol Biotechnol 2014; 24:119-26.
18. Coulthard LR, Geiler J, Mathews RJ et al. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol 2012; 170:36-46.
19. Cros J, Cagnard N, Woollard K et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33:375-386.
20. Orozco G, Hinks A, Eyre S et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. J. Hum Mol Genet 2009; 15:2693-9.
21. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther 2009; 11:R42.
22. Musone SL, Taylor KE, Lu TT et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008; 40:1062-4.
23. Adrianto I, Wen F, Templeton A et al. Association between a functional variant downstream of TNFAIP3 and systemic lupus erythematosus. Nat Genet 2011; 43:253-8.
24. Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011; 39:1086-91.
25. Fung EY, Smyth DJ, Howson JM et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 2009; 10:188-91.
26. Maxwell JR, Gowers IR, Kuet KP, Barton A, Worthington J, Wilson AG. Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. Rheumatology (Oxf) 2012; 51:1514-5.
27. Wang X, Zhu L, Liao Z et al. Alternative expression pattern of MALT1-A20-NF-κB in patients with rheumatoid arthritis. J Immunol Res 2014; 2014:492872.
28. International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45:1353-60.
29. Gilli F, Lindberg RL, Valentino P et al. Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLOS ONE 2010; 5:e8962.
30. Navone ND, Perga S, Martire S, Berchialla P, Malucchi S, Bertolotto A. Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis. J Neuroimmunol 2014; 272:99-102.
31. Steinman L, Merrill JT, McInnes IB, Peakman M. Optimization of current and future therapy for autoimmune diseases. Nat Med 2012; 18:59-65.
32. Richez C, Barnetche T, Khoryati L et al. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Rheumatol 2012; 39:1192-7.
33. Vaitla PM, Radford PM, Tighe PJ et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63:1151-5.